Devyser announced the launch of next generation chimerism analysis solution, strengthening its offering in post-transplant monitoring
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
In this case study, you will hear Dr. Dan Hauzenberger, Medical Director, Section of Transplantation Immunology at Sweden’s Karolinska University Hospital, describing how new, highly sensitive, and precise methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection and treatment to save the lives of transplanted.
In this case study, you will hear Dr. Dan Hauzenberger, Medical Director, Section of Transplantation Immunology at Sweden’s Karolinska University Hospital, describing how new, highly sensitive, and precise methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection and treatment to save the lives of transplanted.
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in...
Read More
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More